vision trial produces positive data in nsclc with met exon 14 mutations
Published 4 years ago • 271 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
3:01
update from chrysalis: amivantamab in patients with nsclc with met exon 14 skipping mutation
-
2:48
vision trial: subset efficacy analyses of tepotinib for nsclc
-
1:14
dr. le on the design of the vision trial in metex14-mutant nsclc
-
13:06
met exon 14 mutations in mnsclc
-
22:16
dr nandini menon | meeting the unmet need in nsclc patients with met exon 14 alterations
-
3:24
off-label crizotinib for the treatment of metex14-mutated nsclc
-
0:49
the importance of metex14 testing in nsclc
-
3:40
metex14 sas (met exon 14 skipping alterations) in non-small cell lung cancer
-
0:49
vision trial demonstrates liquid biopsy is comparable to tissue biopsy for nsclc
-
4:08
targeted therapies in lung cancer
-
1:53
assessing targeted therapies in early stage nsclc
-
18:22
dr vidya veldore - interpretation of met amplification on exon 14 skip mutation in nsclc
-
47:10
ascp project echo® videoconference: key actionable driver mutations in patients with advanced nsclc
-
3:18
best new lung cancer treatments for met mutation
-
4:14
crizotinib in patients with advanced met exon 14-altered nsclc
-
1:00:49
relevant new data sets and advances in targeted therapy for non-small cell lung cancer
-
7:13
new research: stage lv nsclc - new targets (met) - asco 2019
-
1:29:30
management of lung cancer with met alteration
-
0:46
is there a product that would better suit a particular met exon 14 skipping mutations nsclc patient?